Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Stehouwer, CDA
   Heterogeneity of the association between plasma homocysteine and atherothrombotic disease: Insights from studies of vascular structure and function
   CLINICAL CHEMISTRY AND LABORATORY MEDICINE
   
   C.D.A. Stehouwer, "Heterogeneity of the association between plasma homocysteine and atherothrombotic disease: Insights from studies of vascular structure and function", CLIN CH L M, 39(8), 2001, pp. 705-709
2. Leys, D
   Atherothrombosis: A major health burden
   CEREBROVASCULAR DISEASES
   
   D. Leys, "Atherothrombosis: A major health burden", CEREB DIS, 11, 2001, pp. 1-4
3. Bogousslavsky, J
   Benefit of ADP receptor antagonists in atherothrombotic patients: New evidence
   CEREBROVASCULAR DISEASES
   
   J. Bogousslavsky, "Benefit of ADP receptor antagonists in atherothrombotic patients: New evidence", CEREB DIS, 11, 2001, pp. 5-10
4. Becker, RC
   Anticoagulation and the heart
   JOURNAL OF THROMBOSIS AND THROMBOLYSIS
   
   R.C. Becker, "Anticoagulation and the heart", J THROMB TH, 12(1), 2001, pp. 41-52
5. Desai, A; Lankford, HA; Warren, JS
   Homocysteine augments cytokine-induced chemokine expression in human vascular smooth muscle cells: Implications for atherogenesis
   INFLAMMATION
   
   A. Desai et al., "Homocysteine augments cytokine-induced chemokine expression in human vascular smooth muscle cells: Implications for atherogenesis", INFLAMMATIO, 25(3), 2001, pp. 179-186
6. Auer, J; Berent, R; Maurer, E; Mayr, H; Weber, T; Eber, B
   Acute coronary syndromes - An update. Part I: Pathogenesis and drug therapy
   HERZ
   
   J. Auer et al., "Acute coronary syndromes - An update. Part I: Pathogenesis and drug therapy", HERZ, 26(2), 2001, pp. 99-110
7. Serradell, M; Diaz-Ricart, M; Cases, A; Zurbano, MJ; Aznar-Salatti, J; Lopez-Pedre, J; Ordinas, A; Escolar, G
   Uremic medium disturbs the hemostatic balance of cultured human endothelial cells
   THROMBOSIS AND HAEMOSTASIS
   
   M. Serradell et al., "Uremic medium disturbs the hemostatic balance of cultured human endothelial cells", THROMB HAEM, 86(4), 2001, pp. 1099-1105
8. Hoffmeister, HM
   Atherothrombosis and inflammation
   ZEITSCHRIFT FUR KARDIOLOGIE
   
   H.M. Hoffmeister, "Atherothrombosis and inflammation", Z KARDIOL, 90(6), 2001, pp. 379-380
9. Buemi, M; Marino, D; Di Pasquale, G; Floccari, F; Ruello, A; Aloisi, C; Corica, F; Senatore, M; Romeo, A; Frisina, N
   Effects of homocysteine on proliferation, necrosis, and apoptosis of vascular smooth muscle cells in culture and influence of folic acid
   THROMBOSIS RESEARCH
   
   M. Buemi et al., "Effects of homocysteine on proliferation, necrosis, and apoptosis of vascular smooth muscle cells in culture and influence of folic acid", THROMB RES, 104(3), 2001, pp. 207-213
10. Puddu, P; Puddu, GM; Muscari, A
    Current thinking in statin therapy
    ACTA CARDIOLOGICA
    
    P. Puddu et al., "Current thinking in statin therapy", ACT CARDIOL, 56(4), 2001, pp. 225-231
11. Ganne, F; Vasse, M; Beaudeux, JL; Peynet, J; Francois, A; Mishal, Z; Chartier, A; Tobelem, G; Vannier, JP; Soria, J; Soria, C
    Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes -A possible protective mechanism against atherothrombosis
    THROMBOSIS AND HAEMOSTASIS
    
    F. Ganne et al., "Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes -A possible protective mechanism against atherothrombosis", THROMB HAEM, 84(4), 2000, pp. 680-688
12. Fournier, A; Mazouz, H; Pruna, A; Oprisiu, R; Albu, AT; Achard, JM; Fernandez, L
    Stroke prevention and antihypertensive treatment: may angiotensin receptortype I antagonist (AT1RA) be more protective than angiotensin-converting enzyme inhibitor (ACEI)?
    NIEREN-UND HOCHDRUCKKRANKHEITEN
    
    A. Fournier et al., "Stroke prevention and antihypertensive treatment: may angiotensin receptortype I antagonist (AT1RA) be more protective than angiotensin-converting enzyme inhibitor (ACEI)?", NIEREN HOCH, 29(11), 2000, pp. 545-554
13. Ikeda, H; Takajo, Y; Murohara, T; Ichiki, K; Adachi, H; Haramaki, N; Katoh, A; Imaizumi, T
    Platelet-derived nitric oxide and coronary risk factors
    HYPERTENSION
    
    H. Ikeda et al., "Platelet-derived nitric oxide and coronary risk factors", HYPERTENSIO, 35(4), 2000, pp. 904-907
14. van Guldener, C; Stehouwer, CDA
    Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction
    SEMINARS IN THROMBOSIS AND HEMOSTASIS
    
    C. van Guldener e C.D.A. Stehouwer, "Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction", SEM THROMB, 26(3), 2000, pp. 281-289
15. Milionis, HJ; Winder, AF; Mikhailidis, DP
    Lipoprotein (a) and stroke
    JOURNAL OF CLINICAL PATHOLOGY
    
    H.J. Milionis et al., "Lipoprotein (a) and stroke", J CLIN PATH, 53(7), 2000, pp. 487-496
16. Kistler, JP; Furie, KL
    Patent foremen ovale diameter and embolic stroke: A part of the puzzle?
    AMERICAN JOURNAL OF MEDICINE
    
    J.P. Kistler e K.L. Furie, "Patent foremen ovale diameter and embolic stroke: A part of the puzzle?", AM J MED, 109(6), 2000, pp. 506-507
17. Guillot, F
    Atherothrombosis as a marker for disseminated atherosclerosis and a predictor of further ischaemic events - A review
    EUROPEAN HEART JOURNAL SUPPLEMENTS
    
    F. Guillot, "Atherothrombosis as a marker for disseminated atherosclerosis and a predictor of further ischaemic events - A review", EUR H J SUP, 1(A), 1999, pp. A14-A26
18. Nenci, GG
    Unifying concept of arterial vascular disease
    EUROPEAN HEART JOURNAL SUPPLEMENTS
    
    G.G. Nenci, "Unifying concept of arterial vascular disease", EUR H J SUP, 1(A), 1999, pp. A27-A30
19. Kiechl, S; Willeit, J
    The natural course of atherosclerosis - Part I: Incidence and progression
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    
    S. Kiechl e J. Willeit, "The natural course of atherosclerosis - Part I: Incidence and progression", ART THROM V, 19(6), 1999, pp. 1484-1490
20. Petit, L; Lesnik, P; Dachet, C; Moreau, M; Chapman, MJ
    Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages - Relationship to tissue factor induction by cholesterol and oxidized LDL
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    
    L. Petit et al., "Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages - Relationship to tissue factor induction by cholesterol and oxidized LDL", ART THROM V, 19(2), 1999, pp. 309-315
21. Priollet, P
    Arteriopathy of the lower limbs: towards a global medical care
    REVUE DE MEDECINE INTERNE
    
    P. Priollet, "Arteriopathy of the lower limbs: towards a global medical care", REV MED IN, 20(6), 1999, pp. 473-475
22. Guillot, F
    Atherothrombosis as a marker for disseminated atherosclerosis and a predictor of further ischaemic events - A review
    EUROPEAN HEART JOURNAL
    
    F. Guillot, "Atherothrombosis as a marker for disseminated atherosclerosis and a predictor of further ischaemic events - A review", EUR HEART J, 20, 1999, pp. A14-A26
23. Nenci, GG
    Unifying concept of arterial vascular disease
    EUROPEAN HEART JOURNAL
    
    G.G. Nenci, "Unifying concept of arterial vascular disease", EUR HEART J, 20, 1999, pp. A27-A30
24. Mazoyer, E; Drouet, L; Soria, C; Fruchard, JC; Pellerin, A; Arcan, JC; Tobelem, G
    Risk factors and outcomes for atherothrombotic disease in French patients:The RIVAGE study
    THROMBOSIS RESEARCH
    
    E. Mazoyer et al., "Risk factors and outcomes for atherothrombotic disease in French patients:The RIVAGE study", THROMB RES, 95(4), 1999, pp. 163-176
25. Schror, K
    Antiintregrins - new antiplatelet agents for prevention and treatment of acute coronary syndrome
    WIENER KLINISCHE WOCHENSCHRIFT
    
    K. Schror, "Antiintregrins - new antiplatelet agents for prevention and treatment of acute coronary syndrome", WIEN KLIN W, 111(3), 1999, pp. 90-97
26. NEUMAN MP; NEUMAN FJ; NEUMAN J; ROCCELLA MC; MONTENERO Y; BRUETMAN JE; GONZALEZ C
    EFFECT OF BEZAFIBRATE ON LIPID-PEROXIDATION IN PATIENTS WITH HYPERTRIGLYCERIDEMIA
    Advances in therapy
    
    M.P. Neuman et al., "EFFECT OF BEZAFIBRATE ON LIPID-PEROXIDATION IN PATIENTS WITH HYPERTRIGLYCERIDEMIA", Advances in therapy, 15(3), 1998, pp. 142-150
27. AMBROSI P; GARCON D; RIBERI A; HABIB G; BARLATIER A; KREITMANN B; ROLLAND PH; BOUVENOT G; LUCCIONI R; METRAS D
    ASSOCIATION OF MILD HYPERHOMOCYSTEINEMIA WITH CARDIAC GRAFT VASCULAR-DISEASE
    Atherosclerosis (Amsterdam)
    
    P. Ambrosi et al., "ASSOCIATION OF MILD HYPERHOMOCYSTEINEMIA WITH CARDIAC GRAFT VASCULAR-DISEASE", Atherosclerosis (Amsterdam), 138(2), 1998, pp. 347-350
28. BASTARD JP; BRUCKERT E; GIRAL P; BEUCLER I; ANKRI A; HAINQUE B; TURPIN G
    PLASMINOGEN-ACTIVATOR INHIBITOR-1 ANTIGEN LEVELS ARE RELATED TO GAMMA-GLUTAMYL-TRANSFERASE IN HYPERLIPIDEMIC WOMEN
    NMCD. Nutrition Metabolism and Cardiovascular Diseases
    
    J.P. Bastard et al., "PLASMINOGEN-ACTIVATOR INHIBITOR-1 ANTIGEN LEVELS ARE RELATED TO GAMMA-GLUTAMYL-TRANSFERASE IN HYPERLIPIDEMIC WOMEN", NMCD. Nutrition Metabolism and Cardiovascular Diseases, 7(5), 1997, pp. 371-375
29. VALLABHAJOSULA S; FUSTER V
    ATHEROSCLEROSIS - IMAGING TECHNIQUES AND THE EVOLVING ROLE OF NUCLEAR-MEDICINE
    The Journal of nuclear medicine
    
    S. Vallabhajosula e V. Fuster, "ATHEROSCLEROSIS - IMAGING TECHNIQUES AND THE EVOLVING ROLE OF NUCLEAR-MEDICINE", The Journal of nuclear medicine, 38(11), 1997, pp. 1788-1796
30. SIMOPOULOS AP
    OMEGA-3-FATTY-ACIDS IN THE PREVENTION-MANAGEMENT OF CARDIOVASCULAR-DISEASE
    Canadian journal of physiology and pharmacology
    
    A.P. Simopoulos, "OMEGA-3-FATTY-ACIDS IN THE PREVENTION-MANAGEMENT OF CARDIOVASCULAR-DISEASE", Canadian journal of physiology and pharmacology, 75(3), 1997, pp. 234-239
31. JUHANVAGUE I; ALESSI MC; VAGUE P
    THROMBOGENIC AND FIBRINOLYTIC FACTORS AND CARDIOVASCULAR RISK IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS
    Annals of medicine
    
    I. Juhanvague et al., "THROMBOGENIC AND FIBRINOLYTIC FACTORS AND CARDIOVASCULAR RISK IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS", Annals of medicine, 28(4), 1996, pp. 371-380
32. PETERSEN LJ; RINGSDAL VS; LADEFOGED SD; BASLUND B; HANSEN PR
    ANTICARDIOLIPIN ANTIBODIES AND LIPOPROTEIN (A) LEVELS IN PATIENTS WITH CHRONIC-RENAL-FAILURE TREATED WITH DIALYSIS - ASSOCIATIONS WITH ATHEROTHROMBOTIC DISEASE
    International journal of artificial organs
    
    L.J. Petersen et al., "ANTICARDIOLIPIN ANTIBODIES AND LIPOPROTEIN (A) LEVELS IN PATIENTS WITH CHRONIC-RENAL-FAILURE TREATED WITH DIALYSIS - ASSOCIATIONS WITH ATHEROTHROMBOTIC DISEASE", International journal of artificial organs, 19(6), 1996, pp. 339-342
33. FALKENBERG M; TJARNSTROM J; ORTENWALL P; OLAUSSON M; RISBERG B
    LOCALIZATION OF FIBRINOLYTIC ACTIVATORS AND INHIBITORS IN NORMAL AND ATHEROSCLEROTIC VESSELS
    Thrombosis and haemostasis
    
    M. Falkenberg et al., "LOCALIZATION OF FIBRINOLYTIC ACTIVATORS AND INHIBITORS IN NORMAL AND ATHEROSCLEROTIC VESSELS", Thrombosis and haemostasis, 75(6), 1996, pp. 933-938
34. TSCHOEPE D
    ADHESION MOLECULES INFLUENCING ATHEROSCLEROSIS
    Diabetes research and clinical practice
    
    D. Tschoepe, "ADHESION MOLECULES INFLUENCING ATHEROSCLEROSIS", Diabetes research and clinical practice, 30, 1996, pp. 19-24
35. CARTER AM; MANSFIELD MW; STICKLAND MH; GRANT PJ
    BETA-FIBRINOGEN GENE -445-G A POLYMORPHISM AND FIBRINOGEN LEVELS - RISK-FACTORS FOR CORONARY-ARTERY DISEASE IN SUBJECTS WITH NIDDM/
    Diabetes care
    
    A.M. Carter et al., "BETA-FIBRINOGEN GENE -445-G A POLYMORPHISM AND FIBRINOGEN LEVELS - RISK-FACTORS FOR CORONARY-ARTERY DISEASE IN SUBJECTS WITH NIDDM/", Diabetes care, 19(11), 1996, pp. 1265-1268
36. BASTARD JP; BRUCKERT E; ROBERT JJ; ANKRI A; GRIMALDI A; JARDEL C; HAINQUE B
    ARE FREE FATTY-ACIDS RELATED TO PLASMA PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN ANDROID OBESITY
    International journal of obesity
    
    J.P. Bastard et al., "ARE FREE FATTY-ACIDS RELATED TO PLASMA PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN ANDROID OBESITY", International journal of obesity, 19(11), 1995, pp. 836-838
37. MANNUCCI PM
    RECENT PROGRESS IN THE PATHOPHYSIOLOGY OF FIBRINOGEN
    European heart journal
    
    P.M. Mannucci, "RECENT PROGRESS IN THE PATHOPHYSIOLOGY OF FIBRINOGEN", European heart journal, 16, 1995, pp. 25-30
38. ORTH M; LULEY C; MAYER H; WIELAND H
    RESPONSIVENESS OF ATIII AND COAGULATION-FACTOR-V AND COAGULATION-FACTOR-VII TO A STANDARDIZED ORAL FAT LOAD
    Thrombosis research
    
    M. Orth et al., "RESPONSIVENESS OF ATIII AND COAGULATION-FACTOR-V AND COAGULATION-FACTOR-VII TO A STANDARDIZED ORAL FAT LOAD", Thrombosis research, 80(3), 1995, pp. 265-270
39. ORTH M; LULEY C; WIELAND H
    EFFECTS OF VLDL, CHYLOMICRONS, AND CHYLOMICRON REMNANTS ON PLATELET AGGREGABILITY
    Thrombosis research
    
    M. Orth et al., "EFFECTS OF VLDL, CHYLOMICRONS, AND CHYLOMICRON REMNANTS ON PLATELET AGGREGABILITY", Thrombosis research, 79(3), 1995, pp. 297-305
40. SMITH FB; LEE AJ; RUMLEY A; FOWKES FGR; LOWE GDO
    TISSUE-PLASMINOGEN ACTIVATOR, PLASMINOGEN-ACTIVATOR INHIBITOR AND RISK OF PERIPHERAL ARTERIAL-DISEASE
    Atherosclerosis
    
    F.B. Smith et al., "TISSUE-PLASMINOGEN ACTIVATOR, PLASMINOGEN-ACTIVATOR INHIBITOR AND RISK OF PERIPHERAL ARTERIAL-DISEASE", Atherosclerosis, 115(1), 1995, pp. 35-43
41. BOSTOM AG; SHEMIN D; LAPANE KL; MILLER JW; SUTHERLAND P; NADEAU M; SEYOUM E; HARTMAN W; PRIOR R; WILSON PWF; SELHUB J
    HYPERHOMOCYSTEINEMIA AND TRADITIONAL CARDIOVASCULAR-DISEASE RISK-FACTORS IN END-STAGE RENAL-DISEASE PATIENTS ON DIALYSIS - A CASE-CONTROL STUDY
    Atherosclerosis
    
    A.G. Bostom et al., "HYPERHOMOCYSTEINEMIA AND TRADITIONAL CARDIOVASCULAR-DISEASE RISK-FACTORS IN END-STAGE RENAL-DISEASE PATIENTS ON DIALYSIS - A CASE-CONTROL STUDY", Atherosclerosis, 114(1), 1995, pp. 93-103
42. SCANU AM; EDELSTEIN C
    KRINGLE-DEPENDENT STRUCTURAL AND FUNCTIONAL POLYMORPHISM OF APOLIPOPROTEIN
    Biochimica et biophysica acta, L. Lipids and lipid metabolism
    
    A.M. Scanu e C. Edelstein, "KRINGLE-DEPENDENT STRUCTURAL AND FUNCTIONAL POLYMORPHISM OF APOLIPOPROTEIN", Biochimica et biophysica acta, L. Lipids and lipid metabolism, 1256(1), 1995, pp. 1-12
43. ERNST E
    FIBRINOGEN - AN IMPORTANT RISK FACTOR FOR ATHEROTHROMBOTIC DISEASES
    Annals of medicine
    
    E. Ernst, "FIBRINOGEN - AN IMPORTANT RISK FACTOR FOR ATHEROTHROMBOTIC DISEASES", Annals of medicine, 26(1), 1994, pp. 15-22
44. RACCAH D; LASSMANNVAGUE V; ALESSI MC; JUHANVAGUE I; VAGUE P
    INTRAPERITONEAL INSULIN ADMINISTRATION DOES NOT MODIFY PLASMINOGEN-ACTIVATOR INHIBITOR-1 LEVELS IN IDDM PATIENTS
    Diabetes care
    
    D. Raccah et al., "INTRAPERITONEAL INSULIN ADMINISTRATION DOES NOT MODIFY PLASMINOGEN-ACTIVATOR INHIBITOR-1 LEVELS IN IDDM PATIENTS", Diabetes care, 17(8), 1994, pp. 941-942
45. SMITH HA; THOMPSONDOBKIN J; YONAS H; FLINT E
    CORRELATION OF XENON-ENHANCED COMPUTED TOMOGRAPHY-DEFINED CEREBRAL BLOOD-FLOW REACTIVITY AND COLLATERAL FLOW PATTERNS
    Stroke
    
    H.A. Smith et al., "CORRELATION OF XENON-ENHANCED COMPUTED TOMOGRAPHY-DEFINED CEREBRAL BLOOD-FLOW REACTIVITY AND COLLATERAL FLOW PATTERNS", Stroke, 25(9), 1994, pp. 1784-1787
46. CORTELLARO M; COFRANCESCO E; BOSCHETTI C; MUSSONI L; DONATI MB; CARDILLO M; CATALANO M; GABRIELLI L; LOMBARDI B; SPECCHIA G; TAVAZZI L; TREMOLI E; POZZOLI E; TURRI M; CORTELLARO M; COFRANCESCO E; BOSCHETTI C; CARDILLO M; TORRI M; RAINISIO M; GENTILE G; MOREO G; BIANCHI O; LEONARDI P; COLOMBI M; CATALANO M; GALIMBERTI P; RUSSO U; CRESSOTTI A; CARZANIGA G; NOBILI S; NINNO D; DONATI MB; IACOVIELLO L; DEGAETANO G; GABRIELLI L; MARTELLI E; CORSI G; LORENZI G; LOMBARDI B; CARRIERO MR; COLOMBO R; SPECCHIA G; CIOFFI P; SCIRE A; TAVAZZI L; GIANNUZZI P; CORRA U; TEMPORELLI L; MORA F; PICCO D; MORTARA A; ZECCA A; POGGI G; GIBELLINI R; MUSSONI L; TREMOLI E; GIANFRANCESCHI G; COLOMBO A; POZZOLI E; DEAMBROGGI L; DELLAVOLPE A
    INCREASED FIBRIN TURNOVER AND HIGH PAI-1 ACTIVITY AS PREDICTORS OF ISCHEMIC EVENTS IN ATHEROSCLEROTIC PATIENTS - A CASE-CONTROL STUDY
    Arteriosclerosis and thrombosis
    
    M. Cortellaro et al., "INCREASED FIBRIN TURNOVER AND HIGH PAI-1 ACTIVITY AS PREDICTORS OF ISCHEMIC EVENTS IN ATHEROSCLEROTIC PATIENTS - A CASE-CONTROL STUDY", Arteriosclerosis and thrombosis, 13(10), 1993, pp. 1412-1417
47. FOSSATI P
    HYPERCHOLESTEROLEMIA - CONSENSUS AND CONT ROVERSIES ON CHOLESTEROL-LOWERING - WHAT ABOUT IT IN 1993
    Annales d'Endocrinologie
    
    P. Fossati, "HYPERCHOLESTEROLEMIA - CONSENSUS AND CONT ROVERSIES ON CHOLESTEROL-LOWERING - WHAT ABOUT IT IN 1993", Annales d'Endocrinologie, 54(6), 1993, pp. 389-397